Evaluation of serial QuantiFERON ‐ TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐ IL ‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic country
Australasian Journal of Dermatology · 2024
DOI: 10.1111/ajd.14340 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australasian Journal of Dermatology, 2024. Verfasst von Ece Erbağcı und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Uşak University Training and Research Hospital, Uşak, Turkey. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Psoriasis, Interleukin-17, Latent Tuberculosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
In comparison with TNF‐α inhibitors, anti‐IL‐17A agents are considered to have a lower risk of active tuberculosis (TB) or latent TB infection (LTBI) reactivation.
Methods
In this study, we aimed to evaluate the TB infection status and serial QuantiFERON‐TB‐Gold in tube test (QFT) results of psoriasis patients using IL‐17 inhibitors (secukinumab [SEC] and ixekizumab [IXE]) in a real‐world setting from a tuberculosis‐endemic country. Patients who used an anti‐IL‐17 agent for at least 3 months in our follow‐up were included in the study. Patients' clinical and demographic features, baseline QFT results and latest QFT results (if any), and TB infection status were noted from the past medical records.
Results
A total of 717 patients, of whom 333 (46.4%) were female, were included in the study. The cumulative exposure time to an anti‐IL‐17 agent was 14,147 patient‐months, 9743 patient‐months for SEC and 4404 patient‐months for IXE. Also, 459 (SEC = 305/IXE = 154) patients used an anti‐IL‐17 agent for ≥ 12 months. Of these, 125 had positive baseline QFT results. In all, 334 had negative baseline QFT results. The latest QFT result of 309 was also negative (persistent seronegative group). During follow‐up, the QFT results of 10 patients changed from negative to positive (positive seroconversion group). Seven of them were using SEC and three were using IXE, respectively. No case of active TB infection was detected.
Conclusion
In our study, the positive seroconversion rate of 10/334 seems high, but this did not translate to active disease. However, closer monitoring may be required, especially in patients with advanced age, the presence of PsA, long disease duration and long anti‐IL‐17 treatment duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Uşak University Training and Research Hospital, Uşak, Turkey.
- Department of Dermatology and Venereology, İzmir Demokrasi University Buca Seyfi Demirsoy Training and Research Hospital, İzmir, Turkey.
ORCID-Profile: Ece Erbağcı, Sema Koç Yıldırım
Zitieren
APA
Erbağcı, E., Koç Yıldırım, S., & Hapa, F. A. (2024). Evaluation of serial QuantiFERON ‐ TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐ IL ‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic country. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14340
Vancouver
Erbağcı E, Koç Yıldırım S, Hapa FA. Evaluation of serial QuantiFERON ‐ TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐ IL ‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic country. Australasian Journal of Dermatology. 2024. doi:10.1111/ajd.14340
BibTeX
@article{Erbac2024,
author = {Erbağcı, Ece and Koç Yıldırım, Sema and Hapa, Fatma Aslı},
title = {Evaluation of serial QuantiFERON ‐ TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐ IL ‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic country},
journal = {Australasian Journal of Dermatology},
year = {2024},
doi = {10.1111/ajd.14340}
}
EUVIMED